Study of a single dose of tiotropium for asthma triggered by allergens
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests if taking one dose of tiotropium can reduce the breathing trouble caused by allergens (like dust mites or pollen) in people with mild to moderate asthma. It aims to see if this medication can protect your lungs during an allergen challenge.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have mild to moderate asthma (your lung function is at least 65% of normal).
- You show a strong allergic reaction to common allergens like dust mites, grass, cat, or horse dander.
- Your asthma is stable—no respiratory infections or flare-ups needing emergency care in the last 4 weeks.
- You are a non-smoker or an ex-smoker with less than 10 pack-years of smoking history.
- Women who can have children must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new, non-invasive way to measure airway inflammation after breathing in an allergen (like pollen or dust mite). It is for people with mild asthma that is well controlled with only a rescue inhaler.
This Phase 1 study looks at how the immune system drives allergic airway inflammation in people with allergic asthma, and compares them with allergic non-asthma and non-allergic healthy volunteers. The goal is to identify immune “signals” and cell “receptors” involved, which may guide better future treatments.
This study tests if a new albuterol inhaler works as well as the standard one for people with mild asthma. You'll breathe in a medicine that measures how your lungs respond, helping show the new inhaler is safe and effective.
This study checks whether a new albuterol inhaler works the same way as a reference inhaler in adults with stable, mild asthma. It may help you (and others) by confirming that the inhaler delivers the right effect and is safe to use.
This Phase 2 trial tests whether FB825 can improve symptoms and safety in adults with moderate-to-severe allergic asthma. It is mainly for people whose asthma is not well controlled despite regular inhaler treatment.
This study tests a new combination inhaler (budesonide/albuterol) against another asthma inhaler in adults whose asthma is not well controlled on their current medications. It aims to see if the new inhaler can reduce serious asthma attacks and improve symptoms.
Hear when a new Asthma Bronchiale trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.